Loading data for MPLT — first visit, this takes a few seconds.

Alert

MapLight Therapeutics Inc... (MPLT)

NasdaqGS: MPLT · Real-Time Price · USD

11.21

-0.02 (-0.18%)

At close: Aug 24, 2026, 5:39 PM

The price, the headline numbers and the latest news, in one place.

-0.18% (1D)

No data available

Bid	8.1
Market Cap	519.43M
Revenue (ttm)	n/a
Net Income (ttm)	-229.83M
	n/a
	-19.96
	n/a
	-3.36
P/B (ttm)	1.46
P/S (ttm)	n/a
Earnings Date	Nov 12, 2026

Ask	14.28
Volume	435,506
Avg. Volume (20D)	818,343
Open	11.35
Previous Close	11.23
Day's Range	11.06 - 11.61
52-Week Range	9.10 - 40.43
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About MPLT

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 27, 2025

Employees 133

Stock Exchange NasdaqGS

Ticker Symbol MPLT

Website https://www.maplightrx.com

Full Company Profile

Financial Performance

In 2025, MapLight Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's n/a. Earnings were -161.15M, an increase of undefined%.

Financial Statements

Earnings Surprise

MapLight Therapeutics has released their quarterly earnings on Aug 13, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -1.32 misses estimates by -0.01, with -Infinity% YoY decline.

Next Earnings Release

MapLight Therapeutics Inc. is scheduled to release its earnings on Nov 12, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

6 days ago · BioPharma Dive

AstraZeneca scores in lung cancer; Sandoz inks a China deal

A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.

1 week ago · MT Newswires

MapLight Therapeutics Launching $150 Million Private Placement Financing

MapLight Therapeutics (MPLT) said Thursday it has signed an agreement with investors to sell securit

3 weeks ago · BioPharma Dive

MapLight CEO on what investors missed in the biotech’s schizophrenia data

Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."

3 weeks ago · Clinical Trials Arena

MapLight Therapeutics stock crashes on Phase II schizophrenia data

MapLight said the twice-daily dose met the primary endpoint of the schizophrenia trial, but the daily dose did not.

4 weeks ago · Stocktwits

MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose

MapLight announced topline findings from its mid-stage ZEPHYR trial of ML-007C-MA, an oral medicine tested in about 307 adults hospitalized for a sudden worsening of schizophrenia symptoms, on Monday.

Page 1 of 2

MapLight Therapeutics Inc... (MPLT)